EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of GuaB Inhibitors to Treat Mycobacterium tuberculosis Infection

Eric M Kofoed iD, Terry D Crawford iD, Christine M Bowman, Jessica Sims, Tahnee J Dening iD, Shumei Wang, Yuebiao Zhou iD, Seth F Harris, Min Xu, Ping Wu, Ying Yang, Manda K Wong iD und 18 weitere

ACS Infectious Diseases · 09.10.2026 · 12 (10) · 3373-3384

DOI: 10.1021/acsinfecdis.6c00350 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 12.09.2026. Verfasst von Eric M Kofoed und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, California94080-4990, United States. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, IMP Dehydrogenase, Enzyme Inhibitors. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium tuberculosis (Mtb) is responsible for more deaths per year than any other infectious disease. Resistance of circulating Mtb to the standard of care treatment regimen is an urgent global health crisis for which novel antibiotic treatments are needed. We have developed extremely potent, orally bioavailable, small-molecule inhibitors of inosine 5′-monophosphate dehydrogenase (GuaB) that catalyze the rate-limiting step in de novo guanine biosynthesis. The inhibitors exhibited bactericidal activity against Mtb in extracellular, intracellular, and hypoxic environments that capture features of advanced disease pathology in patients. Mtb GuaB2 inhibitors (GuaBi) were efficacious in three different in vivo mouse models of Mtb lung infection: the C57BL/6 super acute, C57BL/6 chronic, and C3HeB/FeJ (Kramnik) models. In the chronic BALB/c infection model of primarily intracellular Mtb, no benefit was observed, whereas in the C3HeB/FeJ model, a bedaquiline, pretomanid, and moxifloxacin treatment regimen that included GuaBi led to a rapid elimination of culturable Mtb infection in half of the mice. Notably, the C3HeB/FeJ model recapitulates advanced pathophysiology and heterogeneous disease that includes caseous necrotic granulomas, intracellular and extracellular reservoirs of Mtb, and lethal progressive infection. These results support further evaluation of a GuaBi-containing therapeutic regimen in relapse-capable preclinical models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsIMP DehydrogenaseEnzyme InhibitorsTuberculosisAnimalsMiceDisease Models, AnimalMice, Inbred C57BLMice, Inbred BALB CFemaleMice, Inbred C3HHumansDiarylquinolinesNitroimidazoles

Stichwörter der Autor:innen

AntibioticsAntimicrobialGuaBKramnikMycobacteriumTuberculosis

Substanzen

Antitubercular AgentsIMP DehydrogenaseEnzyme InhibitorsbedaquilinepretomanidDiarylquinolinesNitroimidazoles

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, California94080-4990, United States.
  • Department of Drug Metabolism and Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, California94080-4990, United States.
  • Department of Developmental Sciences Safety Assessment, Genentech Inc., 1 DNA Way, South San Francisco, California94080-4990, United States.
  • Synthetic Molecule Pharmaceutical Sciences Department, Genentech Inc., 1 DNA Way, South San Francisco, California94080-4990, United States.
  • Department of Structural Biology, Genentech Inc., 1 DNA Way, South San Francisco, California94080-4990, United States.
  • Department of Translational Immunology, Genentech Inc., 1 DNA Way, South San Francisco, California94080-4990, United States.

ORCID-Profile: Eric M Kofoed, Terry D Crawford, Tahnee J Dening, Yuebiao Zhou, Manda K Wong, Michael F T Koehler

Förderung

  • NIGMS NIH HHS
  • Genentech

Zitieren

APA

Kofoed, E. M., Crawford, T. D., Bowman, C. M., Sims, J., Dening, T. J., Wang, S., Zhou, Y., Harris, S. F., Xu, M., Wu, P., Yang, Y., Wong, M. K., Corpuz, R., Xu, Y., Ganti, A., Ubhayakar, S., Hu, C., Clark, K. R., Cai, Z., …, & Tan, M. W. (2026). Development of GuaB Inhibitors to Treat Mycobacterium tuberculosis Infection. ACS Infectious Diseases, 12(10), 3373-3384. https://doi.org/10.1021/acsinfecdis.6c00350

Vancouver

Kofoed EM, Crawford TD, Bowman CM, Sims J, Dening TJ, Wang S, et al. Development of GuaB Inhibitors to Treat Mycobacterium tuberculosis Infection. ACS Infectious Diseases. 2026;12(10):3373-3384. doi:10.1021/acsinfecdis.6c00350

BibTeX
@article{Kofoed2026,
  author = {Kofoed, Eric M and Crawford, Terry D and Bowman, Christine M and Sims, Jessica and Dening, Tahnee J and Wang, Shumei and Zhou, Yuebiao and Harris, Seth F and Xu, Min and Wu, Ping and Yang, Ying and Wong, Manda K and Corpuz, Racquel and Xu, Yiming and Ganti, Anjani and Ubhayakar, Savita and Hu, Chloe and Clark, Kevin R and Cai, Zhijuan and Lai, Kwong Wah and Wang, Xiaojing and Zhang, Renwei and Koehler, Michael F T and Hanan, Emily J and Aliagas, Ignacio and Ng, Julie and Silverman, Jared and Mdluli, Khisimuzi and Kapadia, Sharookh and Tan, Man-Wah},
  title = {Development of GuaB Inhibitors to Treat Mycobacterium tuberculosis Infection},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {10},
  pages = {3373--3384},
  doi = {10.1021/acsinfecdis.6c00350}
}
Kostenlos starten →